StockUS listing USNBYNYSE MKTHealthcareEarnings Deterioration

NovaBay Pharmaceuticals Inc(NBY) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk50Moderate
75%Data
Strong 31% profit margin · Revenue down 79% YoY
USD —+0.00 (+0.00%) Previous close · NYSE MKT
Market cap 40.49M
Reward Ratingⓘ39 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ50 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NBY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is NovaBay Pharmaceuticals Inc?

manufactures and sells wound care products.

AI Brief Pro

The brief on NovaBay Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is NovaBay Pharmaceuticals Inc?

manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 40.49M, and a P/E ratio of 0.1x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (39)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio0.0601
Beta0.007
Insider Activity
12M windowNo data
No insider activity data available for this ticker.